Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Memorial Sloan Kettering Cancer Center at ASCO 2025
Memorial Sloan Kettering Cancer Center (MSK) is proud to honor the work of our physician-scientists and researchers presenting at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 - June 3 in Chicago.
Check back here throughout the five-day meeting for the latest updates, presentation highlights, news releases, and award recipients.
Schedule of MSK Presenters
Find out when MSK experts are presenting during the ASCO meeting.
MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.
Learn about a new approach to helping reduce the risk of stomach and esophageal cancer coming back after surgery, thanks to a clinical trial with immunotherapy led by researchers at MSK.
A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits. Dr. Kevin Liou presented the results of the study at the annual meeting of the American Society of Cancer Oncology (ASCO), on June 1.
Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.
Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).
Memorial Sloan Kettering Cancer Center (MSK) announced that Cardinale Smith, MD, PhD, has joined the institution as the inaugural Chief Medical Officer (CMO). Dr. Smith is also an active ASCO volunteer currently serving as a member of the nominating committee and Chair of the ASCO Annual Meeting Education Program Committee.
Connect with MSK at #ASCO25
Follow us on X and Bluesky for live updates from Chicago and use #ASCO25 to engage with us throughout the ASCO meeting.
Members of the media interested in speaking with MSK experts, please contact: Courtney Nowak Manager, Media Relations Memorial Sloan Kettering Cancer Center denicolc@mskcc.org
Request an appointment
Call 800-525-2225
We’re available 24 hours a day, 7 days a week (Eastern time)
